Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines
Journal
Oral Oncology
Journal Volume
49
Journal Issue
9
Pages
872-877
Date Issued
2013
Author(s)
D'Cruz A
Lin T
Anand A.K
Atmakusuma D
Calaguas M.J
Chitapanarux I
Cho B.C
Goh B.C
Guo Y
Hsieh W.S
Hu C
Kwong D
Lin J.C
Lu T
Prabhash K
Sriuranpong V
Tang P
Vu V.V
Wahid I
Ang K.K
Chan A.T.
Abstract
Head and neck cancer (HNC) is a disease of the upper aerodigestive tract and is one of the most frequently diagnosed cancers worldwide. A high rate of cancers involving the head and neck are reported across the Asian region, with notable variations between countries. Disease prognosis is largely dependent on tumor stage and site. Patients with early stage disease have a 60-95% chance of cure with local therapy. Early diagnosis and appropriate treatment are important to increase the likelihood of cure and survival. However, the majority of patients present with locally advanced disease and require multimodality treatment. This necessitates, a multidisciplinary approach which is essential to make appropriate treatment decisions, particularly with regards to tolerability, costs, available infrastructure and quality of life issues. Unfortunately, majority of the studies that dictate current practice have been developed in the west where diseases biology, patient population and available infrastructure are very different from those in the Asian continent. With this in mind an expert panel of Head and Neck Oncologists was convened in May 2012 to review the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) clinical practice guidelines and develop practical recommendations on the applicability of these guidelines on the management of head and neck cancer for Asian patients. The objective of this review and consensus meeting was to suggest revisions, to account for potential differences in demographics and resources, to the NCCN and ESMO guidelines, to better reflect current clinical management of head and neck cancer within the Asian region for health care providers. These recommendations, which reflect best clinical practice within Asia, are expected to benefit practitioners when making decisions regarding optimal treatment strategies for their patients. ? 2013 Elsevier Ltd. All rights reserved.
Subjects
Asia; Guidelines; Head and neck cancer
Other Subjects
bleomycin; capecitabine; cetuximab; cisplatin; docetaxel; doxorubicin; fluorouracil; gemcitabine; ifosfamide; irinotecan; methotrexate; navelbine; oxaliplatin; paclitaxel; platinum; taxane derivative; Asia; cancer chemotherapy; cancer prognosis; cancer radiotherapy; cancer recurrence; cancer staging; cancer surgery; clinical decision making; clinical practice; endoscopic surgery; head and neck cancer; health care personnel; human; hypopharynx carcinoma; intensity modulated radiation therapy; laryngectomy; larynx cancer; lip cancer; medical society; metastasis; mouth cancer; mouth cavity; nasopharynx cancer; neck dissection; oropharynx carcinoma; positron emission tomography; practice guideline; priority journal; radiation dose; randomized controlled trial (topic); review; thyroidectomy; Asia; Guidelines; Head and neck cancer; Asia; Consensus; Head and Neck Neoplasms; Humans; Practice Guidelines as Topic; Prognosis
Type
review